(thirdQuint)TAXUS PERSEUS Small Vessel.

 This is a prospective, multi-center, single-arm superiority trial to assess the TAXUS(R) Element cent Paclitaxel-Eluting Coronary Stent System for the treatment of de novo atherosclerotic lesions of 20 mm in length in native coronary arteries with visual RVD of 2.

25 mm to < 2.

75 mm diameter.

 Two hundred twenty-four (224) subjects will be treated with the TAXUS Element stent at a maximum of 35 clinical sites.

 Follow-up at 30 days, 9 months including angiography) and 1 year will be completed in all subjects enrolled in the study.

 Eligible subjects will have annual follow-up until 5 years post-index procedure.

.

 TAXUS PERSEUS Small Vessel@highlight

The purpose of the TAXUS PERSEUS Small Vessel trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS(R) ElementTM) for the treatment of de novo atherosclerotic lesions of up to 20 mm in length in native coronary arteries of 2.

25 mm to < 2.

75 mm diameter.

